Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
0.05 USD 0.00(0%)
Last update at 2026-11-13T14:30:00Z
Market Cap
32.54M

Momentum Score

…

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications. The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources. The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. This segment also offers flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items. The Medical Devices segment develops EasyFill Automated Capsule System, a robotic lab device. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The company sells its products directly to end users and distributors. The company was formerly known as International Isotopes Inc. and changed its name to Radnostix, Inc. in December 2025. Radnostix, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.05
Low
0.05
High
52 Week Price Range
0.05
Low
0.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

International Isotopes Inc. develops and supplies medical and specialty isotopes and related services for diagnostic, therapeutic and industrial applications and appears positioned in the nuclear medicine supply chain. Long-term growth drivers may include rising demand for diagnostic and therapeutic isotopes, recurring supply shortages that could support additional producers, and possible capacity expansion initiatives. Investors may find exposure to a specialized, regulated niche with structural demand pressure appealing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
11.23M
Revenue Per Share
0.02
Gross Profit TTM
6.04M
Debt / Equity
-
ROE
-93.04%
Net Debt
0.24M
ROCE
-6.90%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.91M 0.01M -0.87M 0.30M -0.79M
Minority interest - - - 0.00M -0.11M
Net income -0.91M 0.01M -0.87M 0.30M -0.90M
Selling general administrative 8.22M 8.03M 7.58M 6.96M 6.15M
Gross profit 7.70M 8.65M 7.38M 6.29M 5.74M
Reconciled depreciation 0.40M 0.40M 0.35M 0.37M 0.61M
Ebit - - - - -0.24M
Ebitda - - - 1.29M 0.61M
Operating income -0.96M 0.01M -0.78M -1.20M -0.68M
Other operating expenses - - - - 0.44M
Interest expense 0.34M 0.33M 0.33M 0.61M 0.79M
Interest income 0.08M 0.12M 0.08M 0.01M 0.00M
Net interest income -0.26M -0.21M -0.25M -0.60M -0.79M
Total revenue 13.07M 13.90M 12.27M 11.18M 9.66M
Total operating expenses 14.03M 13.89M 13.04M 12.38M 10.34M
Cost of revenue 5.37M 5.25M 4.89M 4.89M 3.92M
Total other income expense net 0.31M 0.21M 0.16M 2.11M 0.68M
Net income from continuing ops -0.91M 0.01M -0.87M 0.30M -0.79M
Net income applicable to common shares - - - - -0.90M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 17.84M 17.16M 16.91M 16.24M 16.33M
Intangible assets 3.21M 3.37M 3.54M 3.70M 3.86M
Other current assets 0.64M 0.70M 0.67M 1.02M 1.00M
Total liab 14.14M 12.81M 12.87M 11.90M 13.60M
Total stockholder equity 3.69M 4.35M 4.04M 4.34M 2.73M
Deferred long term liab - - - - 0.25M
Other current liab - - - - 0.91M
Common stock - - - - 5.03M
Capital stock 5.28M 5.24M 5.20M 5.15M 5.03M
Retained earnings -128.23M -127.32M -127.33M -126.46M -126.76M
Other liab - - - - 0.89M
Good will 1.38M 1.38M 1.38M 1.38M 1.38M
Other assets - - - - 1.08M
Cash 1.70M 1.95M 2.69M 2.38M 0.47M
Total current liabilities 3.97M 3.33M 3.27M 3.51M 4.93M
Net debt 0.24M 0.26M - - 1.49M
Short long term debt 0.16M 0.31M 0.16M 0.64M 1.28M
Property plant equipment - - - - 6.75M
Total current assets 4.63M 4.99M 5.76M 5.74M 3.26M
Net tangible assets - - - - -2.51M
Net receivables 1.42M 1.52M 1.47M 1.60M 0.85M
Long term debt 1.77M 1.90M 1.89M 1.03M 0.68M
Inventory 0.88M 0.82M 0.93M 0.74M 0.92M
Accounts payable 1.53M 0.86M 0.56M 0.38M 1.42M
Non currrent assets other 1.49M 1.43M 0.88M 0.84M 0.83M
Non current assets total 13.21M 12.18M 11.15M 10.50M 13.07M
Capital lease obligations 2.91M 2.09M 2.24M 2.37M 2.50M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.69M -0.15M 3.88M -0.21M
Change to liabilities - - - - -0.61M
Total cashflows from investing activities - - - - -0.21M
Net borrowings -0.30M -0.16M -0.09M - -0.09M
Total cash from financing activities -0.28M -0.15M -0.08M -0.47M -0.08M
Change to operating activities - - - - 0.24M
Net income -0.91M 0.01M -0.87M 0.30M -0.90M
Change in cash -0.19M -0.19M 0.35M 1.91M -0.45M
Begin period cash flow 3.38M 3.57M 3.22M 1.31M 1.75M
End period cash flow 3.19M 3.38M 3.57M 3.22M 1.31M
Total cash from operating activities 0.62M 0.64M 0.58M -1.50M -0.16M
Issuance of capital stock 0.02M 0.01M 0.01M 0.08M 0.02M
Depreciation 0.40M 0.40M 0.35M 0.37M 0.65M
Change to inventory -0.05M 0.11M -0.18M 0.18M -0.09M
Change to account receivables 0.10M -0.05M 0.13M -0.74M -0.08M
Other cashflows from financing activities - - - - -0.00M
Change to netincome - - - - 0.22M
Capital expenditures 0.53M 0.72M 0.15M 0.12M 0.21M
Change in working capital 0.92M -0.02M 0.59M -1.05M -0.53M
Stock based compensation 0.12M 0.20M 0.46M 0.35M 0.08M
Other non cash items 0.09M 0.07M 0.05M 0.32M 0.44M
Free cash flow 0.09M -0.08M 0.43M -1.62M -0.37M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INIS
International Isotopes Inc
-
-%
0.05 - 16.78 2.90 17.34 3.27 92.27
MKKGY
Merck KGaA ADR
0.45
1.38%
33.07 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
2.27
1.38%
167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.31
1.47%
21.43 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.15 - 10.66 0.01 1.16 2.94 23.11

Profile*

International Isotopes Inc

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications. The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources. The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. This segment also offers flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items. The Medical Devices segment develops EasyFill Automated Capsule System, a robotic lab device. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The company sells its products directly to end users and distributors. The company was formerly known as International Isotopes Inc. and changed its name to Radnostix, Inc. in December 2025. Radnostix, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.

4137 Commerce Circle, Idaho Falls, ID, United States, 83401

208 524 5300

44

Name Title Year Born
Mr. Stephen T. Laflin Pres, CEO & Director 1957
Mr. W. Matthew Cox B.S., CPA CFO & Sec. 1984
Mr. Shahe Bagerdjian President, CEO & Director 1984
Mr. W. Matthew Cox B.S., CPA CFO & Secretary 1984

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…